Normal and neoplastic urothelial stem cells: getting to the root of the problem

Most epithelial tissues contain self-renewing stem cells that mature into downstream progenies with increasingly limited differentiation potential. It is not surprising that cancers arising from such hierarchically organized epithelial tissues retain features of cellular differentiation. Accumulating evidence suggests that the urothelium of the urinary bladder is a hierarchically organized tissue, containing tissue-specific stem cells that are important for both normal homeostasis and injury response. The phenotypic and functional properties of cancer stem cells (CSCs; also known as tumour-initiating cells) from bladder cancer tissue have been studied in detail. Urothelial CSCs are not isolated by a 'one-marker-fits-all' approach; instead, various cell surface marker combinations (possibly reflecting the cell-of-origin) are used to isolate CSCs from distinct differentiation subtypes of urothelial carcinomas. Additional CSC markers, including cytokeratin 14 (CK14), aldehyde dehydrogenase 1 family, member A1 (ALDH1A1), and tumour protein 63 (p63), have revealed prognostic value for urothelial carcinomas. Signalling pathways involved in normal stem cell self-renewal and differentiation are implicated in the malignant transformation of different subsets of urothelial carcinomas. Early expansion of primitive CK14+ cells—driven by genetic pathways such as STAT3—can lead to the development of carcinoma in situ, and CSC-enriched urothelial carcinomas are associated with poor clinical outcomes. Given that bladder CSCs are the proposed root of malignancy and drivers of cancer initiation and progression for urothelial carcinomas, these cells are ideal targets for anticancer therapies.

[1]  R G Sweet,et al.  Fluorescence Activated Cell Sorting , 2020, Definitions.

[2]  R. Knuechel,et al.  The human urothelium consists of multiple clonal units, each maintained by a stem cell , 2011, The Journal of pathology.

[3]  M. Cronin,et al.  Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. , 2007, Clinical chemistry.

[4]  J. She,et al.  Identification of side population cells from bladder cancer cells by DyeCycle Violet staining , 2008, Cancer biology & therapy.

[5]  W. Jian,et al.  Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. , 2012, Cancer research.

[6]  J. Bromberg.  Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.

[7]  R. Millikan,et al.  Focus on bladder cancer. , 2004, Cancer cell.

[8]  L. Marchionni,et al.  An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. , 2011, Cancer research.

[9]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[10]  M. Elhilali,et al.  Cellular heterogeneity in normal and neoplastic human urothelium: a study using murine monoclonal antibodies. , 1987, British Journal of Cancer.

[11]  C. Cordon-Cardo,et al.  Loss of p63 expression is associated with tumor progression in bladder cancer. , 2002, The American journal of pathology.

[12]  J. Brosens,et al.  Gene expression: Oestrogen receptor hijacked , 2003, Nature.

[13]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[14]  P. Beachy,et al.  Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder , 2011, Nature.

[15]  R G Sweet,et al.  Fluorescence activated cell sorting. , 1972, The Review of scientific instruments.

[16]  Irving L Weissman,et al.  Plasticity of Adult Stem Cells , 2004, Cell.

[17]  B. Buchholz,et al.  Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin. , 2012, Anticancer research.

[18]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[19]  I. Weissman,et al.  Purification and characterization of mouse hematopoietic stem cells. , 1988, Science.

[20]  Andrew H. Beck,et al.  Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma , 2012, Proceedings of the National Academy of Sciences.

[21]  Jin Yang,et al.  Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer. , 2012, Cancer letters.

[22]  G. Parmigiani,et al.  Differentiation of a Highly Tumorigenic Basal Cell Compartment in Urothelial Carcinoma , 2009, Stem cells.

[23]  I. Weissman,et al.  A role for Wnt signalling in self-renewal of haematopoietic stem cells , 2003, Nature.

[24]  C. Dinney,et al.  p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers , 2012, PloS one.

[25]  L. Neckers,et al.  Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer‐initiating cells , 2012, International journal of cancer.

[26]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  N. Malats,et al.  PIK3CA MUTATIONS ARE AN EARLY GENETIC ALTERATION ASSOCIATED WITH FGFR3 MUTATIONS IN SUPERFICIAL PAPILLARY BLADDER TUMORS , 2006 .

[28]  G. Apodaca,et al.  Cell biology and physiology of the uroepithelium. , 2009, American journal of physiology. Renal physiology.

[29]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[30]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[31]  A. Smith,et al.  Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. , 1998, Genes & development.

[32]  Ekaterini Blaveri,et al.  Bladder cancer outcome and subtype classification by gene expression. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  C. Abbou,et al.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[34]  J. Nichols,et al.  Functional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem Cells , 2003, Cell.

[35]  G. Apodaca.  The Uroepithelium: Not Just a Passive Barrier , 2004, Traffic.

[36]  F. Lloyd,et al.  Cystitis glandularis and adenocarcinoma of the bladder. , 1971, The Journal of urology.

[37]  I. Weissman,et al.  Isolation of a candidate human hematopoietic stem-cell population. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Y. Barrandon,et al.  Oligopotent stem cells are distributed throughout the mammalian ocular surface , 2008, Nature.

[39]  Xiaowei Yin,et al.  Subpopulations of Stem-like Cells in Side Population Cells from the Human Bladder Transitional Cell Cancer Cell Line T24 , 2009, The Journal of international medical research.

[40]  I. Giannopoulou,et al.  Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome. , 2009, European Journal of Surgical Oncology.

[41]  I. Weissman,et al.  Clonal analysis of hematopoietic stem-cell differentiation in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Austin G Smith,et al.  The Liberation of Embryonic Stem Cells , 2011, PLoS genetics.

[43]  C. Cordon-Cardo,et al.  Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.

[44]  M. Kreft,et al.  Urothelial injuries and the early wound healing response: tight junctions and urothelial cytodifferentiation , 2005, Histochemistry and Cell Biology.

[45]  Jennifer Southgate,et al.  Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. , 2005, Experimental cell research.

[46]  Mogens Kruhøffer,et al.  Gene Expression in the Urinary Bladder , 2004, Cancer Research.

[47]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[48]  T. Ørntoft,et al.  Squamous cell metaplasia of the bladder urothelium. A retrospective study of 36 patients , 1992, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[49]  G. Steinberg,et al.  Urothelial carcinoma of the bladder: definition, treatment and future efforts , 2011, Nature Reviews Urology.

[50]  Anirban P. Mitra,et al.  Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. , 2010, European urology.

[51]  J. Southgate,et al.  Role of PPAR γ and EGFR signalling in the urothelial terminal differentiation programme , 2004, Journal of Cell Science.

[52]  A. Witteveen,et al.  Converting a breast cancer microarray signature into a high-throughput diagnostic test , 2006, BMC Genomics.

[53]  Irving L. Weissman,et al.  Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells , 2003, Nature.

[54]  K. Kihara,et al.  Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[56]  H. Samaratunga,et al.  Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study , 2004, Histopathology.

[57]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[58]  K. Kihara,et al.  PPARγ ligands suppress proliferation of human urothelial basal cells in vitro , 2002 .

[59]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[60]  R. Knuechel,et al.  Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer , 2011, Virchows Archiv.

[61]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[62]  R. Romih,et al.  Reorganisation of the urothelial luminal plasma membrane in the cyclophosphamide treated rats , 2006, Pflügers Archiv.

[63]  Scott Lowe,et al.  Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. , 2011, The American journal of pathology.

[64]  T. H. van der Kwast,et al.  Characterization of distinct functions for growth factors in murine transitional epithelial cells in primary organotypic culture. , 1994, Experimental cell research.

[65]  J. Southgate,et al.  Effects of PPAR agonists on proliferation and differentiation in human urothelium. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[66]  A. S. Conner,et al.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.

[67]  S. Bastacky,et al.  Bladder permeability barrier: recovery from selective injury of surface epithelial cells. , 2002, American journal of physiology. Renal physiology.

[68]  G. Lin,et al.  Label retaining and stem cell marker expression in the developing rat urinary bladder. , 2012, Urology.

[69]  I. Weissman,et al.  Stem Cells Units of Development, Units of Regeneration, and Units in Evolution , 2000, Cell.

[70]  C. Potten,et al.  Epithelial stem cells in vivo , 1988, Journal of Cell Science.

[71]  F. Watt,et al.  Epidermal stem cells: an update. , 2006, Current opinion in genetics & development.

[72]  J. Chang,et al.  Bladder Cancer Initiating Cells (BCICs) Are Among EMA−CD44v6+ Subset: Novel Methods for Isolating Undetermined Cancer Stem (Initiating) Cells , 2008, Cancer investigation.

[73]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Rudolf Jaenisch,et al.  Ectopic Expression of Oct-4 Blocks Progenitor-Cell Differentiation and Causes Dysplasia in Epithelial Tissues , 2005, Cell.

[75]  C. Cordon-Cardo,et al.  Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. , 1992, Journal of the National Cancer Institute.

[76]  B. Czerniak,et al.  Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. , 1992, Human pathology.

[77]  Erika Pastrana,et al.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells. , 2011, Cell stem cell.

[78]  K. Johnson.  An Update. , 1984, Journal of food protection.

[79]  Jens-Peter Volkmer,et al.  Three differentiation states risk-stratify bladder cancer into distinct subtypes , 2012, Proceedings of the National Academy of Sciences.

[80]  Zhenqiu Liu,et al.  Aldehyde Dehydrogenase 1 A1–Positive Cell Population Is Enriched in Tumor-Initiating Cells and Associated with Progression of Bladder Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[81]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[82]  K. Kiguchi,et al.  Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. , 2004, The Journal of clinical investigation.

[83]  K. Kihara,et al.  PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. , 2002, Journal of cellular physiology.

[84]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[85]  M. Loda,et al.  p63 regulates commitment to the prostate cell lineage. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[86]  I. Weissman,et al.  Cancer stem cells in bladder cancer: a revisited and evolving concept , 2010, Current opinion in urology.

[87]  M. Frank,et al.  The therapeutic promise of the cancer stem cell concept. , 2010, The Journal of clinical investigation.

[88]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[89]  D. Chopin,et al.  Growth, differentiation and senescence of normal human urothelium in an organ-like culture. , 2004, European urology.

[90]  S. Hayward,et al.  Growth factors in bladder wound healing. , 1997, The Journal of urology.

[91]  D. Neal,et al.  Original Articles: Bladder Cancer , 1995 .

[92]  François Vaillant,et al.  Generation of a functional mammary gland from a single stem cell , 2006, Nature.

[93]  K. Baggerly,et al.  Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy , 2008, Laboratory Investigation.

[94]  R. Isseroff,et al.  Label-retaining cells of the bladder: candidate urothelial stem cells. , 2008, American journal of physiology. Renal physiology.

[95]  M. Knowles,et al.  Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. , 2010, Urologic oncology.

[96]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[97]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[98]  Jae K. Lee,et al.  A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. , 2011, The Lancet. Oncology.